Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma-Reference-Cited by-同舟云学术

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Published:2016-02-08 Issue:3 Volume:22 Page:270-277
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ambrogio Chiara,Gómez-López Gonzalo,Falcone Mattia,Vidal August,Nadal Ernest,Crosetto Nicola,Blasco Rafael B,Fernández-Marcos Pablo J,Sánchez-Céspedes Montserrat,Ren Xiaomei,Wang Zhen,Ding Ke,Hidalgo Manuel,Serrano Manuel,Villanueva Alberto,Santamaría David,Barbacid Mariano

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4041.pdf

Reference60 articles.

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).

2. Pikor, L.A., Ramnarine, V.R., Lam, S. & Lam, W.L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 82, 179–189 (2013).

3. Meng, D. et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 81, 1–10 (2013).

4. Peters, S., Zimmermann, S. & Adjei, A.A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat. Rev. 40, 917–926 (2014).

5. Gridelli, C. et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat. Rev. 40, 300–306 (2014).

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF‐1α Ubiquitination and Degradation;Advanced Science;2024-07-18

2. Discovery of LLC355 as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1;Journal of Medicinal Chemistry;2024-05-10

3. Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis;European Journal of Medicinal Chemistry;2024-02

4. Altered Treg Infiltration after Discoidin Domain Receptor 1 (DDR1) Inhibition and Knockout Promotes Tumor Growth in Lung Adenocarcinoma;Cancers;2023-12-08

5. Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study;Clinical Orthopaedics & Related Research;2023-09-27